AbCellera Biologics logo
AbCellera Biologics ABCL
$ 3.36 -1.18%

Annual report 2025
added 02-24-2026

report update icon

AbCellera Biologics Financial Ratios 2011-2026 | ABCL

Annual Financial Ratios AbCellera Biologics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-6.6 -5.3 -10.4 16.0 15.7 50.5 - - - - - - - - -

P/S

12.8 29.8 40.2 5.2 6.4 25.7 - - - - - - - - -

EPS

-0.5 -0.6 -0.5 0.6 0.6 0.5 -0.0 - - - - - - - -

EV (Enterprise Value)

1.22 B 1.01 B 1.7 B 2.44 B 2.19 B 5.58 B 13.2 M 9.88 M - - - - - - -

EBITDA per Share

-0.67 -1.03 -0.78 0.79 0.79 0.99 - - - - - - - - -

EV/EBITDA

9.2 50.3 - - - - - - - - -

PEG

- 0.01 - - - - - - - - -

P/B

1.0 0.8 1.3 2.1 2.3 7.2 - - - - - - - - -

P/CF

-7.3 -7.9 -34.8 9.2 9.8 264.6 - - - - - - - - -

ROE %

-15.14 -15.42 -12.70 12.85 14.96 14.32 - - - - - - - - -

ROA %

-10.79 -11.97 -9.84 10.29 11.64 11.83 - - - - - - - - -

ROCE %

-16.80 -24.52 -17.33 15.22 17.06 17.30 - - - - - - - - -

Current Ratio

3.5 4.5 4.4 5.0 4.5 5.7 - - - - - - - - -

DSO

173.4 202.4 - - - - - - - - - - - - -

Operating Cycle

173.4 202.4 - - - - - - - - - - - - -

Cash Conversion Cycle

173.4 202.4 - - - - - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios AbCellera Biologics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.19 -0.12 -0.15 - -0.17 -0.13 -0.14 - -0.1 -0.11 -0.14 - 0.09 -0.02 0.59 - -0.08 -0.01 0.43 - -0.02 0.03 -0.01 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.24 -0.15 -0.19 - -0.19 -0.19 -0.17 - -0.18 -0.17 -0.21 - 0.15 -0.01 0.81 - -0.09 -0.01 0.6 - -0.01 - -0.01 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-18.57 -17.39 -17.26 -11.66 -14.08 -11.76 -10.99 -8.29 -6.16 -1.61 0.38 15.53 13.29 8.92 9.24 9.76 9.44 11.36 12.41 0.23 0.23 0.56 -0.25 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-13.75 -13.21 -13.35 -9.06 -10.95 -9.17 -8.55 -6.56 -4.84 -1.23 0.33 11.88 10.05 6.51 6.74 8.36 8.09 9.65 10.52 0.19 0.19 0.46 -0.21 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-21.71 -22.92 -26.17 -18.14 -22.05 -18.84 -15.50 -12.15 -9.54 -3.01 -0.00 18.31 15.81 10.70 10.66 12.05 11.85 14.16 14.71 -0.53 -0.53 -0.33 -0.24 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

3.5 3.5 4.2 4.5 4.4 4.7 4.4 4.4 4.6 4.5 5.2 5.0 5.1 4.2 4.1 4.5 5.3 6.2 6.6 5.8 5.8 5.8 5.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

719.7 356.8 1029.8 - - - - - - - - - - - - - 23.2 43.2 5.5 - - 3.7 8.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

719.7 356.8 1029.8 - - - - - - - - - - - - - 23.2 43.2 5.5 - - 3.7 8.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

719.7 356.8 1029.8 - - - - - - - - - - - - - 23.2 43.2 5.5 - - 3.7 8.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company AbCellera Biologics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
$ 3.44 2.99 % $ 303 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 218.06 -1.72 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Amgen Amgen
AMGN
$ 349.77 0.57 % $ 188 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.23 -1.38 % $ 899 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.6 0.76 % $ 6.06 B irlandaIrlanda
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Inventiva S.A. Inventiva S.A.
IVA
$ 6.08 5.19 % $ 138 M franceFrance
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.4 2.19 % $ 357 M britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.63 0.77 % $ 16.5 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 11.19 1.91 % $ 461 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.42 4.25 % $ 734 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.82 -4.08 % $ 3.29 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA